Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Rznomics Inc. logo — Development of innovative treatments for cancer & intractabl...

Rznomics Inc.

Development of innovative treatments for cancer & intractable diseases through the RNA-based platform technology

Founded 2017 Korea South Korea South 11 employees Series C Total: $59.70B Biopharma, Biotechnology

General Information

Company Name Rznomics Inc.
Founded Year 2017
Location Korea South Korea South +1
Employees 11
Industries Biopharma, Biotechnology
Funding Stage Series C
Social

Get notified when Rznomics Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Rznomics Inc.

Rznomics Inc. is a biopharmaceutical startup focused on developing innovative treatments for cancer and intractable diseases through its RNA-based platform technology called trans-splicing ribozyme. Established in 2017, Rznomics has gained recognition from bio-focused institutions and successfully raised a total of KRW 60.9 billion in funding, including a recent KRW 37.2 billion series C investment from Korea Development Bank, Partners Investment, IBK Capital, UTC 2019 BioVentureFund, QUAD Ventures, Shinhan Venture Investment, Aon, and SBI Investment Korea. In 2022 1H, Rznomics achieved a significant milestone with the approval of its RZ-001 IND submission for the HCC treatment by the MFDS, and the clinical trial for RZ-001 is underway. The company also boasts a robust pipeline including treatments for glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Additionally, Rznomics is actively engaging in partnerships with global companies to explore opportunities for co-research, co-development, and licensing. Rznomics' dedication to developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease, coupled with its strategic partnerships and substantial funding, positions the company as a promising player in the biopharma and biotechnology industries.

Taxonomy: biopharmaceuticals, RNA-based platform technology, oncology, genetic disease, trans-splicing ribozyme, clinical trials, new drug development, gene therapy, Alzheimer's disease, global partnerships, TIPS program, innovation, research funding, tagging not forced

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 8
Investor Investor Investor Investor Investor Investor Investor Investor
08 Jun 2022
Series B •••••• 2
Investor
•••• •••• 		16 Apr 2021
Series A •••••• - 30 Oct 2019

Rznomics Inc. Alternatives & Competitors

Rznomics Inc. vs
Locanabio, Inc.
Locanabio, Inc. United States

Creating RNA-targeting gene therapies to treat devastating diseases

Series B
7 employees
Biotechnology, Health Care
Rznomics Inc. vs
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. United States

The Power of RNA Amplified

Series A
22 employees
Biotechnology
Rznomics Inc. vs
RiboNova, Inc.
RiboNova, Inc. United States

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also...

Series Unknown
7 employees
Biotechnology, Pharmaceutical

FAQ About Rznomics Inc.

Development of innovative treatments for cancer & intractable diseases through the RNA-based platform technology
Rznomics Inc. was founded in 2017.
Rznomics Inc. is headquartered in Korea South.
Rznomics Inc. operates in the following industries: Biopharma, Biotechnology.
Rznomics Inc. has approximately 11 employees.
Rznomics Inc. has completed 3 funding rounds, raising a total of $59.70B. The latest funding stage is Series C.
Top alternatives and competitors to Rznomics Inc. include Locanabio, Inc., Replicate Bioscience, Inc., RiboNova, Inc., ReviR Therapeutics, Acetylon Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rznomics Inc. and Locanabio, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Rznomics Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy